Bone Biologics Corp (BBLG): Price and Financial Metrics
GET POWR RATINGS... FREE!
BBLG Price/Volume Stats
| Current price | $0.17 | 52-week high | $1.97 |
| Prev. close | $0.18 | 52-week low | $0.14 |
| Day low | $0.17 | Volume | 210,008 |
| Day high | $0.18 | Avg. volume | 432,683 |
| 50-day MA | $0.22 | Dividend yield | N/A |
| 200-day MA | $0.48 | Market Cap | 2.81M |
BBLG Stock Price Chart Interactive Chart >
Bone Biologics Corp (BBLG) Company Bio
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. Its NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. The company is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. Its platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
Latest BBLG News From Around the Web
Below are the latest news stories about BONE BIOLOGICS CORP that investors may wish to consider to help them evaluate BBLG as an investment opportunity.
BBLG: Bone Biologics Announces the Approval of A Vital TrialBy Brad Sorensen, CFA NASDAQ:BBLG READ THE FULL BBLG RESEARCH REPORT Bone Biologics (NASDAQ:BBLG) announced that it has received approval to begin pilot clinical trials with NB1 in spinal fusion patients. The approval was given by the Human Research Ethics Committee and the trials will take place in Australia. This is an important and exciting step for Bone as the study will evaluate the safety |
Bone Biologics Receives Human Research Ethics Committee Approval to Begin Pilot Clinical Trial with NB1 in Spinal Fusion Patients in AustraliaBURLINGTON, Mass., April 11, 2023--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, announces that the Human Research Ethics Committee (HREC) has approved Monash Health as the first of a planned multicenter pilot clinical trial to evaluate the Company’s NB1 bone graft in Australia. |
BBLG: BBLG Provides Investment Opportunity Before TrialsBy Brad Sorensen, CFA NASDAQ:BBLG READ THE FULL BBLG RESEARCH REPORT Bone Biologics (NASDAQ:BBLG) continues to be a company that we are excited about as it pursues a way to improve the outcomes of spinal fusion surgery, while also having the potential to impact trauma and osteoporosis applications in a positive way. The Nell-1 technology is about to enter human clinical trials and recently |
Bone Biologics Advances Preparations for NB1 Pilot Clinical Trial with Engagement of Contract Research OrganizationBURLINGTON, Mass., January 26, 2023--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, announces it has engaged Avania as the contract research organization (CRO) for the Company’s pilot clinical trial with NB1. Avania is an integrated global, full-service CRO with specialized expertise in medical devices, novel technology and drug-device combination products. The trial will evaluate the safety and effectiveness of Bone Biologic’s novel NB |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayWe're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about for Tuesday morning! |
BBLG Price Returns
| 1-mo | -34.62% |
| 3-mo | -46.37% |
| 6-mo | -39.31% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -18.93% |
| 2022 | -94.04% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...